Dyax DX-88 Submission Likely Postponed For Additional Dosing Study
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks a subcutaneous dose-ranging study on the recombinant protein to treat hereditary angioedema.
You may also be interested in...
Dyax DX-88 Anticipated Approval Pushed Back to 2008
Company will conduct a confirmatory placebo-controlled trial following FDA recommendation.
Dyax DX-88 Anticipated Approval Pushed Back to 2008
Company will conduct a confirmatory placebo-controlled trial following FDA recommendation.
Kos Could Launch Icatibant For Hereditary Angioedema In 2007
The firm expects to report top-line data from two ongoing Phase III studies in the third quarter.